Navigation Links
3SBio Inc. Announces Unaudited Third Quarter 2009 Results
Date:11/12/2009

) on a GAAP basis, and increased by 19.0% over the first nine months of 2008 to RMB75.8 million (US$11.1 million) on a non-GAAP basis. -- Net income per ADS on a fully-diluted basis for the first nine months of 2009 was RMB3.24 (US$0.47) compared with RMB1.89 (US$0.28) for the first nine months of 2008 on a GAAP basis, and RMB3.52 (US$0.52) compared with RMB2.93 (US$0.43) for the first nine months of 2008 on a non-GAAP basis. Third Quarter 2009 Business Highlights -- EPIAO, the Company's flagship injectable recombinant human erythropoietin ("EPO") product, demonstrated strong growth with net revenue from EPIAO in the third quarter of 2009 rising 32.6% to RMB56.6 million (US$8.3 million) compared to RMB42.7 million (US$6.3 million) in the third quarter of 2008. -- Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin ("TPO") product, increased by 41.3% to RMB27.9 million (US$4.1 million) in the third quarter of 2009, compared to RMB19.7 million (US$2.9 million) in the third quarter of 2008. -- Construction of the new EPIAO and TPIAO manufacturing plant in Shenyang remains on schedule for completion this year in preparation for validation and certification next year. -- Dr. Jing Lou, chief executive officer of 3SBio, commented: "Overall, the business is performing as expected with a strong set of results this quarter and we reiterate our full-year guidance of US$43-45 million. Construction of our new plant remains on schedule and we look forward to moving to validation and certification next year. We continued to develop our product pipeline and will update the market when we have reached significant milestones in the approval process." Three months ended September 30, 2009 Unaudited Financial Results

Net revenues. Net revenues increased by 35.8% to R
'/>"/>

SOURCE 3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. 3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009
2. 3SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009
3. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
4. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
5. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
6. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
7. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
8. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
9. 3SBio Inc. Announces Third Quarter 2008 Results
10. 3SBio Inc. Files for SFDA Approval of NuLeusin
11. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - ... offering. The global companion diagnostics market ... from 2014 to 2019. Factors such as rising need ... companion diagnostics by the pharmaceutical industry, support from regulatory ...
(Date:9/18/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ... but separate underwritten offerings of 10,000,000 shares of its ... $2.00 per share, for expected gross proceeds of $20 ... Preferred Stock at a price to the public of ... million. Each share of Series A Convertible Preferred Stock ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... ... Advisory Board --, SAN DIEGO, July ... it has received regulatory approval to,begin a Phase 2a proof-of-concept clinical ... metabolic arthritis, is a,painful and debilitating disease caused by abnormally elevated ...
... July 9 ATS Medical, Inc.,(Nasdaq: ATSI ... and services, today announced it has obtained new ... of the ATS Open,Pivot(R) Mechanical Heart Valve., ... Open Pivot valve was implanted in Lausanne, Switzerland,on ...
... Genetics,Corporation (CellCyte) (OTC Bulletin Board: CCYG) has engaged ... financial advice and,services. CellCyte seeks to build shareholder ... will work with InCap to initiate a corporate,partnering ... expander and stem cell delivery technologies., "We ...
Cached Biology Technology:Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 2Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 4ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 4
(Date:9/18/2014)... PULLMAN, Wash. - Washington State University researchers have developed ... sediment to power waste cleanup in rural areas. ... lead to an inexpensive and quick way to clean ... treatment plants while reducing pollution. , Professor Haluk ... College of Engineering and Architecture discuss the system in ...
(Date:9/18/2014)... a small, icy moon of Uranus, is one of ... solar system. Despite its relatively small size, Miranda appears ... resulted in the formation of at least three remarkable ... , These coronae are visible in Miranda,s southern ... across. Arden corona, the largest, has ridges and troughs ...
(Date:9/18/2014)... team of researchers from McGill University and the ... of polyethylene ,microbeads, Canadian Journal of Fisheries ... originate from cosmetics, household cleansers, or industrial cleansers, ... Owing to their small size and buoyancy, they ... Microplastics are a global contaminant in the world,s ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Microplastic pollution discovered in St. Lawrence River sediments 2
... -- Many shark populations have plummeted in the past three ... fins, as an incidental catch of fisheries targeting other species, ... species. However, until now, a lack of data prevented scientists ... a large geographic scale. In a study published online ...
... Medical Center has been successful in attracting funding of ... funding was awarded in response to an application to ... (hemostaseologist) currently based in the USA, to the Center ... of the application was announced jointly by the Alexander ...
... plant disease normally found in subarctic climates has been identified ... far south as Herefordshire., Sclerotinia subarctica , a fungus ... been found in carrots and meadow buttercups in Perthshire by ... of Life Sciences at the University of Warwick. , It ...
Cached Biology News:Scientists provide first large-scale estimate of reef shark losses in the Pacific Ocean 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 3